Baudax Bio logo
Baudax Bio BXRX

Quarterly report 2023-Q3
added 11-20-2023

report update icon

Baudax Bio Financial Ratios 2011-2026 | BXRX

Annual Financial Ratios Baudax Bio

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.0 -0.0 -0.2 -2.5 - - - - - - - -

P/S

0.6 0.3 25.2 - - - - - - - - -

EPS

-177.3 -361.2 -142.9 -3.5 -7.9 - - - - - - -

EV (Enterprise Value)

29.8 M 24.5 M 65.6 M 134 M 103 M 95.2 M - - - - - -

EBITDA per Share

-171 -343 -5.74 -4.98 - - - - - - - -

EV/EBITDA

-2.0 0.2 -1.3 - - - - - - - -

PEG

- 0.0 -0.04 - - - - - - - -

P/B

-0.0 0.0 -0.8 -4.8 - - - - - - - -

P/CF

-0.0 -0.0 -0.3 -1.6 - - - - - - - -

ROE %

242.53 -149.47 514.22 194.71 - - - - - - - -

ROA %

-586.07 -37.11 -110.72 -60.05 - - - - - - - -

ROCE %

234.36 -143.70 -110.28 -101.23 - - - - - - - -

Current Ratio

0.3 1.3 2.0 2.6 - - - - - - - -

DSO

126.1 100.2 37.8 - - - - - - - - -

DIO

- 595.6 627.6 - - - - - - - - -

DPO

140.5 382.2 769.8 - - - - - - - - -

Operating Cycle

126.1 695.9 665.3 - - - - - - - - -

Cash Conversion Cycle

-14.3 313.6 -104.5 - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Baudax Bio

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.3 -1.51 4.91 - -98.7 -41.95 -126.87 - -7.03 -7.17 -9.46 - 0.64 -1.72 -4.03 - -1.1 -1.13 -0.46 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.21 -1.44 -2.02 - -12.1 -20.9 -75.4 - -6.77 -7.6 -9.08 - -0.66 -1.7 -4.02 - -1.09 -1.12 -0.45 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

52.84 154.79 -92.35 -188.71 -106.88 -145.89 367.40 2118.45 2039.49 1878.70 1749.22 399.07 460.76 601.40 458.97 150.90 150.90 89.21 25.93 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-49.38 -206.79 -190.63 -211.49 -239.07 -99.85 -102.17 -70.90 -53.90 -9.32 -32.85 -85.92 -104.95 -140.98 -116.20 -46.54 -101.06 -136.54 -117.02 -54.51 -54.51 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

162.21 159.66 4.40 -152.74 -73.72 -9.48 436.60 2077.87 2160.72 2164.56 2012.05 559.69 621.16 599.77 458.70 150.39 150.39 88.92 25.70 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

0.9 0.9 0.5 0.3 0.5 1.1 1.2 1.3 0.8 0.9 1.0 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.3 0.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

- - - - 178.1 186.2 124.3 - 104.1 86.7 49.3 - 68.4 13.3 28.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

- - - - 367.6 1322.9 719.2 - 777.0 492.9 319.6 - 503.2 418.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

14483.3 4240.1 792.5 - 252.0 802.3 334.6 - 385.5 251.1 266.4 - 617.3 512.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - 545.7 1509.0 843.5 - 881.1 579.6 368.9 - 571.7 431.4 28.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

-14483.3 -4240.1 -792.5 - 293.6 706.7 508.9 - 495.6 328.5 102.5 - -45.6 -81.4 28.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Baudax Bio, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.64 8.07 % $ 85.4 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.66 -1.48 % $ 8.81 B australiaAustralia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 21.36 4.86 % $ 998 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.47 5.0 % $ 378 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.92 - $ 4.81 M israelIsrael
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.19 2.7 % $ 448 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.12 -0.37 % $ 3.07 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.59 1.09 % $ 2.16 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.47 -1.34 % $ 391 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 4.25 8.35 % $ 286 B britainBritain
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 2.22 2.3 % $ 461 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.82 1.13 % $ 27.9 M israelIsrael
Cabaletta Bio Cabaletta Bio
CABA
$ 3.2 2.24 % $ 322 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA